Gene · 4824
NKX3-1: NK3 homeobox 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. NKX3-1: NK3 homeobox 1. Genes, record 4824. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4824
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99801 | Homeobox protein Nkx-3.1 | 234 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 10696 | Q99801 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15399 | Q99801 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 10696 | Q99801 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15399 | Q99801 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 15399 | Q99801 | Espacenet |
| EP 4487869 A2 | 2025-01-08 | 222 | Q99801 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 7356 | Q99801 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 15238 | Q99801 | Espacenet |
| KR 1020240027895 A | 2024-03-04 | 414 | Q99801 | Espacenet |
| JP 2023036863 A | 2023-03-14 | 414 | Q99801 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,220
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | NKX3-1 papers | Newest fiscal year |
|---|---|---|---|
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 56 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 42 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 38 | 2025 |
| P01CA163227 | Androgen Receptor Action in Castration Resistant Prostate Cancer | 36 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 26 | 2025 |
| P50CA186786 | Michigan Prostate SPORE 2025-2030 | 19 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 18 | 2025 |
| P50CA092629 | SPORE in Prostate Cancer | 18 | 2025 |
| P30CA013696 | Cancer Center Support Grant | 16 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 16 | 2025 |
1 to 10 of 2,220Source NIH's project files
See all 2,220 nih grantsPapers3,429
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Primary Neoplasms of the Seminal Vesicles: A Narrative Review of Carcinoma and the Rarer Non-Epithelial and Biphasic Tumours. | Diagnostics (Basel) | 2026 | 42793728 | PubTator, text mining | PubMed |
| NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor. | Semin Oncol | 2026 | 42762807 | PubTator, text mining | PubMed |
| Urothelial carcinoma of the bladder with prostatic stromal invasion and early postoperative bone metastases: a case report. | Front Urol | 2026 | 42698475 | PubTator, text mining | PubMed |
| Occult Esophageal Squamous Cell Carcinoma Presenting as Bone-Predominant Carcinoma of Unknown Primary: A Case Report of a p40-Negative Vertebral Metastasis. | Diagnostics (Basel) | 2026 | 42651078 | PubTator, text mining | PubMed |
| Reappraisal of Endobronchial Polypoid Adenocarcinoma of the Lung: A Clinicopathological Analysis of 11 Cases. | Am J Surg Pathol | 2026 | 42638334 | PubTator, text mining | PubMed |
| Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications. | Biochim Biophys Acta Rev Cancer | 2026 | 42637058 | PubTator, text mining | PubMed |
| Occult Metastatic Prostate Carcinoma Presenting With Decompensated Heart Failure and Bicytopenia. | Cureus | 2026 | 42597963 | PubTator, text mining | PubMed |
| Prostate Cancer Recurrence Mimicking a Primary Paranasal Sinus Tumor on 18F-FDG PET/CT During Treatment for Metastases After 10 Years of Remission. | Case Rep Radiol | 2026 | 42569055 | PubTator, text mining | PubMed |
| Enzalutamide promotes an early plasticity-associated transcriptional state without terminal neuroendocrine differentiation in prostate cancer cells. | Front Oncol | 2026 | 42568401 | PubTator, text mining | PubMed |
| Prostate Cancer Associated with Muir-Torre Syndrome: A Rare Case Report and Literature Review. | Case Rep Oncol | 2026 | 42541269 | PubTator, text mining | PubMed |
1 to 10 of 3,429
See all 3,429 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4824
GET https://conductscience.org/api/genes/v1/4824/patents?page=2